Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: Tumor response and predictive value of diffusion-weighted MR imaging in five patients

Journal of Vascular and Interventional Radiology

Volumn 23, Issue 7, 2012, Pages 937-941

  Venturini, Massimo ^a   Pilla, Lorenzo ^a   Agostini, Giulia ^a   Cappio, Stefano ^a   Losio, Claudio ^a   Orsi, Marcello ^a   Ratti, Francesca ^a   Aldrighetti, Luca ^a   De Cobelli, Francesco ^a,b   Del Maschio, Alessandro ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; IOPROMIDE; IRINOTECAN; LIDOCAINE; MORPHINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG RESPONSE; ENUCLEATION; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HUMAN; LIVER METASTASIS; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTON THERAPY; SURVIVAL TIME; UVEA MELANOMA;

AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; DELAYED-ACTION PREPARATIONS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MELANOMA; MICROSPHERES; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 84862882661     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2012.04.027     Document Type: Article

References (12)

1. Peters S, Voelter V, Zografos L, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17:578-593.
2. Francken AB, Accort NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distal recurrence in patients with cutaneous melanoma. Ann Oncol 2008; 15:1476-1484.
3. Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 2010; 74:e38-e44.
4. Voelter V, Schalenbourg A, Pampallona S, et al. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res 2008; 18:220-224. (Pubitemid 351684668)
5. Gonsalves CF, Enschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastases of uveal melanoma: a single-institution experience. AJR Am J Roentgenol 2011; 196:468-473.
6. Fiorentini G, Aliberti C, Del Conte A, et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009; 23:131-138.
7. Park SH, Moon WK, Cho N, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010; 257:56-63.
8. Fiorentini G, Aliberti C, Benea G, et al. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology 2008; 55:2077-2082.
9. Martin RC, Howard J, Tomalty D, et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010; 33:960-966.
10. Martin RC, Joshi J, Robbins K, Tomalty D, O'Hara R, Tatum C. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol 2009; 2009:539-795.
11. Dumez H, Awada A, Piccart M, et al. A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. Ann Oncol 2006; 17:1158-1165. (Pubitemid 43985254)
12. Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 2007; 30:7-14. (Pubitemid 44908921)